Chao Dong

Chao Dong

Auto-generated profile, based on publicly available information

Chao Dong

Department of Neurosurgery, The Sixth Medical Center of PLA General Hospital, Beijing, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of Clinical Neurology
Verified
Journal Article
Open access
PDF file
CZChunhui Zhou
Chunhui Zhou
HZHao Zhao
Hao Zhao
FYFan Yang
Fan Yang
LHLuokai Huangfu
Luokai Huangfu
CDChao Dong
Chao Dong
JZJianning Zhang
Jianning Zhang
Zhou C, et al. J Clin Neurol. 2021 Apr;17(2):220-228. https://doi.org/10.3988/jcn.2021.17.2.220

3 July 2015 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
BMBin-Lin Ma
Bin-Lin Ma
MSMei-Hui Shan
Mei-Hui Shan
GSGang Sun
Gang Sun
GRGuang-Hui Ren
Guang-Hui Ren
CDChao Dong
Chao Dong
MZMei Zhou
Mei Zhou
The present study aimed to investigate whether the mammalian target of rapamycin (mTOR) signaling pathway is activated in invasive breast cancer. The expression levels of phosphorylated (p)‑mTOR at ser2448 were detected, as well as the expression levels of its downstream signaling molecules: Eukaryotic translation initiation factor 4E‑binding protein 1 (4E‑BP1), and p70 ribosomal protein S6 kinase 1 (S6K1). The correlation between p‑mTOR, p‑4E‑BP1, p‑S6K1, and the clinicopathological parameters of breast cancer were also determined. p‑mTOR, p‑4E‑BP1 and p‑S6K1 expression was detected in 285 breast cancer tumor samples and adjacent normal tissue samples using immunohistochemistry. The expression levels and the location of the proteins were analyzed and compared in the various tissue samples. Multivariate Cox regression was used to analyze the clinicopathological factors and prognosis associated with the tissue samples. The disease‑free survival rate was examined using survival analyses and Log‑rank tests. The results of the present study indicated that the expression levels of p‑mTOR, p‑4E‑BP1, and p‑S6K1 were significantly higher in breast cancer tissue, as compared with normal tissue (P<0.01). p‑mTOR was predominantly expressed in the cytoplasm, whereas p‑4E‑BP1 and p‑S6K1 were predominantly co‑expressed in the cytoplasm and the nucleus. In addition, p‑4E‑BP1 and p‑S6K1 were more likely to be expressed in the cytoplasm in breast cancer tissue samples, as compared with normal tissue samples (P0.05). Thus suggesting that these markers are not adequate risk factors for disease free survival (P>0.05). In conclusion, the results of the present study suggested that p‑mTOR, p‑4E‑BP1, and p‑S6K1 are activated in invasive breast cancer. In addition, the exclusive expression of p‑4E‑BP1 and p‑S6K1 in the cytoplasm may be characteristic of progressive breast cancer. However, p‑mTOR, p‑4E‑BP1, and p‑S6K1 are not prognostic factors for breast cancer.

1 April 2020 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
SWShuwei Wang
Shuwei Wang
XGXinru Guo
Xinru Guo
WLWenying Lv
Wenying Lv
YLYanteng Li
Yanteng Li
LZLeiming Zhang
Leiming Zhang
CGCheng Gang
Cheng Gang
Introduction: Ribosomal protein SA pseudogene 52 (RPSAP52) has been characterized as an oncogenic lncRNA in pituitary tumors. Analysis of TCGA dataset revealed the upregulation of RPSAP52 in glioblastoma (GBM). We, therefore, investigated the roles of RPSAP52 in GBM. Methods: A total of 50 GBM patients (33 males and 20 females; 54– 75 years; mean age: 61.8± 5.8 years) were selected from the 89 cases of GBM patients. Under the guidance of MRI, brain biopsy was performed to collect GBM tissues from each patient for the diagnosis of GBM. U-373 MG cells were employed and had transient transfections. qRNA, Western blot, and a series of experiments were performed to characterize their associations. Results: The results showed that RPSAP52 was upregulated in GBM patients, and its high expression levels predicted poor survival. In GBM tissues, expression levels of RPSAP52 were significantly and positively correlated with that of TGF-β 1. In GBM tissues, RPSAP52 positively regulated the expression of TGF-β 1. Cell stemness assay showed that, compared to C and NC groups, overexpression of RPSAP52 and TGF-β 1 led to increased, while silencing of RPSAP52 led to decreased CD133+ cells. Overexpression of TGF-β 1 attenuated the effects of RPSAP52 siRNA silencing. Conclusion: Therefore, RPSAP52 upregulates TGF-β 1 to increase cancer cell stemness and predict postoperative survival in GBM.